Dose-dense Capecitabine Schedule [7days on _7 Days Off] in Colorectal Cancer in Comparison With Standered Regimen

Dose_dense Capecitabine Schedule [7days on _7days Off] in Colorectal Cancer in Comparison With Standered Regimen

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07215936

Enrollment

100

Registered

2025-10-14

Start date

2025-09-25

Completion date

2028-09-30

Last updated

2025-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal Cancer

Brief summary

Dose\_dense Capecitabine Schedule in colorectal cancers

Detailed description

Dose\_dense Capecitabine schedule\[7 days on\_7days off\] in colorectal cancer in comparison with standerd regimen

Interventions

DRUGArm A:Dose_dense Capecitabine in Colorectal cancer

Appling dose \_dense Capecitabine 1750mg/m2 for one week then one week off Cycle repeated every 2 weeks

DRUGArm B : standard dose Capecitabine

Pateints will receive capecitabine 1000 mg/m2 for 2 weeks then one week off

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

Dose\_dense capecitabine schedule \[7 days on \_7 days off \] Compared to standerd regimen

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients who diagnosed colorectal cancer Performance status ranging from 0 to 2 Both sexs

Exclusion criteria

* pateints with other malignancy Pateints who have other comorbid diseas

Design outcomes

Primary

Measure	Time frame
1_Quality of life assessed through EORTC_QLQ_CR29 questionaire	2 years

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026